Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. The South African Multicenter ANCHOR Study

American Journal of Hypertension

Volumn 10, Issue 3, 1997, Pages 250-260

  Opie, L H ^a   Muller F O ^b   Myburgh, D P ^c   Rosendorff, C ^d   Sareli, P ^e   Seedat, Y K ^f   Weich, D J V ^b   Luus, H G ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f KING EDWARD VIII HOSPITAL   (South Africa)

Author keywords

ambulatory blood pressure; calcium antagonist; nisoldipine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; NISOLDIPINE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NISOLDIPINE; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED;

EID: 0342941141     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00384-6     Document Type: Article

References (33)

1. McMahon S, Peto R, Cutler J, et al. Blood pressure stroke and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335:1990;765-774.
2. Collins R, Peto R, MacMahon S, et al. Blood pressure stroke and coronary heart disease: part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 335:1990;827-838.
3. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 321:1989;868-873.
4. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens. 2:1989;419-423.
5. Siscovick DS, Raghunathun TE, Psaty BM. Diuretic therapy for hypertension and the risk of primary cardiac arrest. New Engl J Med. 330:1994;1852-1857.
6. Zanchetti A, Chalmers J, Arakawa K. Guidelines for the management of mild hypertension. Memorandum from a WHO/ISH meeting. J Hypertens. 20:((suppl 5)):1993;S34-S41.
7. Kloner RA, Sowers JR, DiBona GF, et al. Sex and age related antihypertensive effects of amlodipine. Am J Cardiol. 77:1996;713-722.
8. Frishman WH, Garofalo JL, Rothschild A, et al. The nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Cardiol. 64:1989;65F-69F.
9. Diemont WL, Stegeman CJ, Beekman J, et al. Low dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension. Am J Hypertens. 4:1991;163S-167S.
10. Thulin T, Almkvist H, Berglund L, et al. Efficacy and tolerability of felodipine ER and diltiazem SR as-monotherapy in primary hypertension: a double-blind randomised study. Cardiovasc Drugs Ther. 8:1994;845-849.
11. Godfraind T, Salomone S, Dessy C. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol. 20:((suppl 5)):1992;S34-S41.
12. Lund-Johansen P, Ormvik P. Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension. J Cardiovasc Pharmacol. 10:((suppl 1)):1987;S139-S148.
13. Rosenthal T, Frohlich ED. Nisoldipine in the treatment of hypertension. Adv Ther. 10:1993;151-156.
14. Mitchell J, Frishman W, Heiman M. Nisoldipine: a new dihydropyridine calcium-channel blocker. J Clin Pharmacol. 33:1993;46-52.
15. Daniels AD, Opie LH. Monotherapy with the calcium antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. Am J Cardiol. 60:1987;703-707.
16. Rosendorff C, Goodman C. Double blind double dummy crossover study of the efficacy and safety of nisoldipine (BAYk5552) versus nifedipine. Curr Ther Res Clin Exp. 50:1985;417-424.
17. Fujii Y, Hattori S, Nagami K. The hypotensive effect of nisoldipine: 24 hour blood pressure profile and serial alterations of renal and hormonal function. Curr Ther Res Clin Exp. 55:1994;93-101.
18. Nakanishi T, Takahashi H, Yoshimura M. Effects of nisoldipine on ambulatory blood pressure in patients with essential hypertension. Curr Ther Res Clin Exp. 50:1991;417-424.
19. Brigden G, Heber M, Caruana M. Once daily nisoldipine in hypertension: cuff and ambulatory intra-arterial blood pressure. Eur J Clin Pharmacol. 37:1989;551-554.
20. O'Brien E, Cox JP, O'Malley K. Ambulatory blood pressure measurements in the evaluation of blood pressure lowering drugs. J Hypertens. 7:1989;243-247.
21. Crager MR, Reitman MA. Running average analysis of clinical trial ambulatory blood pressure data. Biometrics. 47:1991;129-137.
22. Kiowski W, Osswald S. Circadian variation of ischemic cardiac events. J Cardiovasc Pharmacol. 21:((suppl 2)):1993;S45-S48.
23. Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol. 75:1995;41E-45E.
24. Opie LH. Drugs for the Heart. 1995;50-82 W B Saunders, Philadelphia.
25. Poole-Wilson PA, DEFIANT II: Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Lancet (in press).
26. Middlemost SJ, Sack M, Davis J. Effects of long acting nifedipine on casual office blood pressure measurements, 24 hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension. Am J Cardiol. 70:1992;474-478.
27. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med. 328:1993;914-921.
28. Seedat YK. Varying responses to hypotensive agents in different racial groups: black versus white differences. J Hypertens. 7:1989;515-518.
29. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
30. Pahor M, Guralnik JM, Corti M, et al. Long term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 43:1995;1191-1197.
31. Kleinbloesem CH, van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther. 41:1987;26-30.
32. Schall R, Muller OF, Groenewald EM. Single dose and steady state pharmacokinetic and pharmacodynamic profiles of nisoldipine coat-core tablets in healthy young, healthy elderly and elderly hypertensive volunteers. Drug Invest. 8:1994;21-30.
33. Shionoiri H, Minamisawa K, Masumori S. Pharmakokinetics and pharmacodynamics of nisoldipine in hypertensive patients with normal and mild to moderate impaired renal function. Arzneim Forsch/Drug Res. 45:1995;785-789.